EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Amgen's Enterprise Value is $162,210 Mil.
Amgen's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $8,746 Mil. Therefore, Amgen's EV-to-EBIT for today is 18.55.
The historical rank and industry rank for Amgen's EV-to-EBIT or its related term are showing as below:
AMGN'
s EV-to-EBIT Range Over the Past 10 Years
Min: 9.84 Med: 13.17 Max: 22.13
Current: 18.55
During the past 13 years, the highest EV-to-EBIT of Amgen was 22.13. The lowest was 9.84. And the median was 13.17.
AMGN's EV-to-EBIT is ranked worse than 57.14% of 672
companies
in the Drug Manufacturers industry
Industry Median: 15.86
vs AMGN: 18.55
The historical data trend for Amgen's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
EV-to-EBIT
10.94
11.63
15.69
16.53
19.10
Amgen Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
EV-to-EBIT
21.28
18.99
19.10
20.64
18.23
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen EV-to-EBIT Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Amgen's EV-to-EBIT falls into.
Amgen's current Enterprise Value is $162,210 Mil.
Amgen's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $8,746 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (NAS:AMGN) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Amgen's Enterprise Value for the quarter that ended in Jun. 2022 was $159,480 Mil.
Amgen's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $8,746 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Amgen's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.04(0.02%) Volume: 3,733,332 8:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:AMGN has been successfully added to your 
